PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34022417-9 2021 Susceptibility of extended-spectrum beta-lactamase (ESBL)-negative Escherichia coli to ceftaroline ranged from 67.0% in Asia/SP to 91.0% in Africa/ME; susceptibility to amikacin, meropenem and tigecycline was >=96.7% in all regions. T 91825 87-98 EsbL Escherichia coli 18-50 33373731-9 2021 Rates of susceptibility to ceftaroline for ESBL-negative Escherichia coli (n = 442), Klebsiella pneumoniae (n = 381), and Klebsiella oxytoca (n = 103) were 92.1%, 93.2%, and 96.1%, respectively. T 91825 27-38 EsbL Escherichia coli 43-47 25222304-15 2014 Ceftaroline exhibited good activity against non-ESBL phenotype strains of E. coli and Klebsiella spp. T 91825 0-11 EsbL Escherichia coli 48-52 25222304-17 2014 CONCLUSION: Ceftaroline demonstrated potent in vitro activity when tested against S. aureus, S. pneumoniae, H. influenzae, beta-hemolytic streptococci and non-ESBL-phenotype E. coli and Klebsiella spp. T 91825 12-23 EsbL Escherichia coli 159-163 19349512-2 2009 However, the activity of ceftaroline cannot be solely relied upon for eradication of multidrug-resistant gram-negative isolates, such as Pseudomonas aeruginosa and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, which represent a current clinical concern. T 91825 25-36 EsbL Escherichia coli 198-202 24529941-6 2014 Ceftaroline-avibactam was very active against Escherichia coli and Klebsiella pneumoniae (MIC50/90, 0.03/0.06 and 0.06/0.25 mug/mL, respectively) including extended-spectrum beta-lactamase (ESBL) screen-positive phenotypes (MIC50/90, 0.06/0.12 and 0.12/1 mug/mL, respectively). T 91825 0-11 EsbL Escherichia coli 190-194 24529941-9 2014 Ceftaroline-avibactam exhibited a broad-spectrum of in vitro activity against isolates from patients in the USA with ABSSSI including MRSA, beta-hemolytic streptococci, E. coli, and K. pneumoniae as well as ESBL screen-positive phenotype isolates and merits further study in clinical indications where these resistant organisms may be a concern. T 91825 0-11 EsbL Escherichia coli 207-211 19349512-6 2009 Ceftaroline exhibited a MIC range of 0.125 to 1,024 microg/ml and was reduced 2- to 512-fold by combination with tazobactam (4 microg/ml) for ESBL-producing strains. T 91825 0-11 EsbL Escherichia coli 142-146